Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Evaluation of Nicotine Analogs
NCT07585006Phase 1Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 6-methyl nicotine and nicotinamide (6 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Nicotine urges/craving, Nicotine withdrawal symptoms and 1 more. Started May 2026; status: recruiting.
02
Drugs
6-methyl nicotinenicotinamide
Beyond the preview
Go deeper on NCT07585006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585006.